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Abstract
Background: Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) activity is a marker of osteoclast number and is 
elevated in breast cancer (BC) patients with extensive bone metastasis, which might in turn reflect the tumour burden. 
We tested the hypothesis that baseline serum TRACP 5b activity and its interval change are potential prognostic 
markers of survival in BC patients with bone metastasis.
Methods: We analyzed the data from previous prospective studies. A total of 100 patients with newly diagnosed bone 
metastasis were included. Cox proportional regression model was used to evaluate the correlation between the overall 
survival time (OS) and baseline serum TRACP 5b activity and its interval changes. The least significant change (LSC) of 
TRACP 5b was calculated from data obtained from 15 patients with early BC.
Results: Estrogen receptor status (Hazard Ratio (HR) = 0.397; p = 0.003) and visceral metastasis (HR = 0.492; p = 0.0045) 
were significantly correlated with OS. The OS was significantly shorter in those patients with higher baseline TRACP 5b 
activity based on a cut-off value to delineate the highest tertile (HR = 3.524; p < 0.0001). Further analysis demonstrated 
that among patients in the highest tertile, OS was significantly longer in those patients who had achieved a decrease of 
serum TRACP 5b activity greater than the LSC (38.59%) (p = 0.0015).
Conclusions: We found that TRACP 5b activity and its interval change after treatment bore a prognostic role in BC 
patients with bone metastasis and a high baseline serum TRACP 5b activity. Further prospective phase II study is 
necessary to confirm these results.
Background
Breast cancer (BC) is the most common malignancy in
women. Once metastasis occurs, most patients become
i n c u r a b l e .  H o w e v e r ,  m e t a s t a t i c  B C  i s  a  h e t e r o g e n e o u s
disease in which some women survive only a few weeks
whereas others survive many years. Hormonal receptor
status including estrogen receptor (ER) and progesterone
receptor (PR) as well as human epidermal growth factor
receptor 2 (HER2) have been shown to predict treatment
response and survival [1]. Patients with metastasis only to
bone survive longer than those with visceral metastasis
[2]. Nevertheless, patients with bone metastasis still carry
heterogeneous outcomes, and the survival time might
become shorter when skeletal-related events (SRE) such
as pathological fractures, radiation to bones, spinal cord
compression, hypercalcemia, and bone surgery occur to
patients [3]. Biomarkers of bone metabolism are eagerly
sought as a way to predict outcome in BC patients with
bone metastasis [3-5]. In a recent post hoc analysis from a
randomized phase III trial comparing zoledronic acid and
pamidronate in patients with bone metastasis, Lipton et
al. demonstrated that early normalization of elevated
baseline urinary N-telopeptide of type 1 collagen (NTX)
levels was associated with longer event-free and overall
survival (OS) times in BC patients receiving zoledronic
acid[6,7]. Our previous studies demonstrated that NTX
and tartrate-resistant acid phosphatase 5b (TRACP 5b)
have similar clinical performance for the diagnosis of
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bone metastases and treatment monitoring [8]. Further-
more, preanalytical variables such as diurnal rhythm and
feeding influence NTX and other collagen biomarkers
more than TRACP 5b activity [8]. In most clinical prac-
tices it is difficult to standardize the time of blood draw.
Therefore TRACP 5b has certain advantages over colla-
gen biomarkers for assessment of bone metabolism.
TRACP 5b is an enzyme secreted by osteoclasts and its
activity can be measured specifically in serum by immu-
noassay[9]. Serum TRACP 5b activity is a marker of
osteoclast number and becomes elevated in the serum of
individuals with increased bone turnover rate such as
pre-pubertal children and post-menopausal women [9-
11]. We and other investigators have found that serum
TRACP 5b activity could become elevated in BC patients
with bone metastasis because 80% of the bone metastasis
lesions caused by BC are osteolytic in nature [12,13]. Fur-
thermore elevated serum TRACP 5b activity in BC
patients is positively correlated with the extent of bone
metastasis [8,14]. We have also demonstrated that serum
TRACP 5b activity can be potentially used as a marker to
monitor treatment response in BC patients with bone
metastasis and as an adjunct to bone scintigraphy for the
diagnosis and follow-up of bone metastasis [8,14]. In the
current study we hypothesize that an elevated serum
TRACP 5b activity may reflect a higher tumor burden
and further signify a worse outcome in BC patients with
bone metastasis. Therefore we examine if baseline serum
TRACP 5b activity and its interval change after treatment
can be used as prognostic markers for overall survival
time in BC patients with bone metastasis. Confounding
factors including age, tumor markers including carcino-
embryonic antigen (CEA) and CA 15.3, ER, HER2 over-
expression, and the presence of visceral metastasis were
adjusted.
Methods
Study population
We analyzed retrospectively biochemical and clinical
data from 100 BC patients with newly diagnosed bone
metastasis who had participated in our previous studies
of serum TRACP 5b activity in BC [12,13]. ER and HER2
were stained by immunohistochemistry on paraffin-
embedded tumor tissues. Expression levels were deter-
mined semi-quantitatively by a BC pathologist (CPY).
Bone metastasis was diagnosed according to clinical
symptoms, radiological images, and 99mTc-hydroxy-
methylene-diphosphanonate whole-body bone scintigra-
phy. All patients underwent chemotherapy, hormonal
therapy, radiotherapy, and/or bisphosphonates therapy as
clinically indicated. Fifteen informed, consenting subjects
participated as a control group to determine the least sig-
nificant change (LSC) of serum TRACP 5b activity. The
control subjects were females aged 34 to 67 years with a
median age of 50. All were in early stages of BC with no
distant metastasis and undergoing adjuvant treatment as
clinically indicated. All studies were performed under the
guidelines of the Helsinki Declaration and approved by
the Human Subjects Protection Offices (IRB) of Tri-Ser-
vice General Hospital.
Serum TRACP 5b Activity Assay
Serum from each patient had been collected and pro-
cessed at diagnosis of bone metastasis and monthly
thereafter for 6 months or until death as described in pre-
vious studies [12,13]. Osteoclastic TRACP 5b activity was
measured by an antigen capture immunoassay as previ-
ously reported [8,14]. The clinical specificity and sensitiv-
ity of this assay for both osteoporosis and extensive bone
metastasis in BC have been reported previously [14,15].
The analytic precision was estimated as the mean percent
coefficient of variation (%CV) for duplicate measure-
ments. The inter-assay error was determined by repeti-
tive independent assay over a one-week period of aliquots
of six sera ranging in activity from 2.54 to 9.37 μmol/min/
L. The average CV was calculated to be 3.9%. The intra-
assay error was determined by simultaneous assay of
eight duplicates of five sera ranging in activity from 2.50
to 11.0 μmol/min/L; the average CV was calculated to be
5.1%.
Statistical Analyses
All descriptive data are expressed as median (range). The
dependent variable was OS in days or months. Cox pro-
portional regression model (SAS 9.1.3) was used to assess
the association of interest, as well to adjust the potential
confounders of age, tumor marker (CEA, CA 15.3), ER
and HER2 status, and visceral metastasis. To avoid co-lin-
earity among the independent variables, co-linearity
diagnostic analysis was done with the following criteria:
tolerance >0.4 or variance inflation <2.5 and condition
number <10. There was no co-linearity among indepen-
dent variables. Patients were divided into 2 groups
according to their scales of TRACP 5b activities, i.e. the
top 1/3 and the bottom 2/3. Student t test and Chi-square
test were used to assess the allocation between these two
groups. The LSC is the minimum change of TRACP 5b
activity considered to be of biological significance at a
95% level of confidence, a level of confidence normally
used in clinical practice. In this study, we retrieved data
from 15 randomly selected early breast cancer patients
from previous studies to calculate the LSC of serum
TRACP 5b from monthly samples taken over a 4-month
period. The percent change in TRACP 5b was calculated
according to the following formula: Δ = [(baseline data -
subsequent data)/baseline data] × 100%. Cox propor-
tional regression model was used to compare survival of
patients in the highest tertile of baseline TRACP 5b activ-Wu et al. BMC Cancer 2010, 10:158
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ity to the remaining patients in the lower and middle ter-
tiles. The maximal interval change within 6 months for
serum TRACP 5b activity was used to stratify patients
into two groups according to whether the interval change
was greater or less than the LSC. Cox proportional
regression model was used to estimate the significance
and the hazard ratio of each variable in the total cohort,
those in the highest TRACP 5b tertile, and those in the
remaining group separately.
Results
Patient Characteristics
The demographics of the 100 BC patients with bone
metastasis are shown in Table 1. They all were women
ranging in age from 30 to 78 years with a median age of
50. The median OS was 481 days. Fifty-seven percent of
patients had concurrent visceral metastases on the initial
diagnosis of bone metastasis. Sixty-three of the 100
patients were ER-positive, 28 ER-negative, and 9 with
unknown ER status. Eighteen of these patients were
HER2-positive, 57 HER2-negative, and 25 had unknown
HER2 status.
Least Significant Change of TRACP 5b
The LSC of serum TRACP 5b activity over time was cal-
culated from 4 consecutive monthly samples from 15
patients with early BC without distant metastasis. The
LSC of TRACP 5b was 38.59%. This meant that a TRACP
5b change at months 1 to 4 of at least 38.59% was
required to have a 95% level of confidence that a biologi-
cally significant change had occurred. If this change was a
decline in serum TRACP 5b activity, it was considered to
be a positive treatment response and clinical improve-
ment.
Serum TRACP 5b and Overall Survival Time
Table 2 summarizes the results of Cox proportion regres-
sion models assessing the OS as a function of baseline
variables including age, ER status, CEA, CA15.3, HER2
s t a t u s  a n d  v i s c e r a l  m e t a s t a s i s  i n  a d d i t i o n  t o  b a s e l i n e
serum TRACP 5b activity. The presence of visceral
metastasis in addition to bone metastasis as a dichoto-
mous variable (Hazard ratio (HR) = 0.492; p = 0.0045)
c o r r e l a t e d  i n v e r s e l y  w i t h  t h e  O S .  E R  p o s i t i v i t y  a s  a
dichotomous variable correlated positively with a longer
survival (HR = 0.397; p = 0.003). No other continuous
biomarkers showed significant correlation with the OS.
We divided the 100 patients into 2 groups arbitrarily
according to the scale of serum TRACP 5b activity, i.e.
those with the top 1/3 baseline activities (TRACP 5b ≥
5.736 U/L) and the remainders. The demographics and
allocation between these 2 groups are listed in Table 3.
The OS in patients with the highest one-third of serum
TRACP 5b activity was significantly longer (HR = 3.524;
p < 0.001) than for those with the lower two-thirds of
serum TRACP 5b (Table 2, Figure 1). We further calcu-
lated the median baseline serum TRACP 5b activities in
different patient groups stratified by the OS. As shown in
Figure 2, there was an inverse relationship between base-
line serum TRACP 5b activity and OS.
Serum TRACP 5b Interval Changes and the Overall Survival 
Time
In the 100 patients studied, 81 had available serial serum
TRACP 5b activity determinations. No subsequent
TRACP 5b data could be retrieved from the remaining 19
patients, due to either early death or loss to follow up.
The maximal interval change between baseline and fol-
low-up serum TRACP 5b activities (ΔmaxTRACP 5b)
within 6 months of enrollment in each individual patient
was calculated as [(baseline TRACP 5b activity - TRACP
5b activity at maximal alteration)]/baseline TRACP 5b
activity × 100%. The median time to the maximal change
of TRACP 5b activity was 2 month. When the 81 patients'
data were analyzed together, there was no correlation
between ΔmaxTRACP 5b and the OS. However, when
only patients with baseline serum TRACP 5b activities in
the highest tertile (≥5.736 U/L) were analyzed (n = 27),
ΔmaxTRACP 5b, stratified by LSC as a dichotomous vari-
able, i.e. ΔmaxTRACP 5b > or ≤ 38.59%, significantly cor-
Table 1: Characteristics of the 100 breast cancer patients 
with bone metastasis
Female/male 100/0
Median age 50 (30-78)
Median time from initial diagnosis to 
enrollment
1007(2-6801)
Median overall survival time (Days) 481(1-4465)
Median initial TRACP-5b activity (U/L) 3.894 (1.21-
24.245)
Median CEA (ng/ml) 3.5 (1-8165)
Median CA-153 (U/ml) 42.15 (6.59-
3040)
ER positive 63
negative 28
unknown 9
Her-2/neu positive 18
negative 57
unknown 25
Visceral metastasis present 57
Bone metastasis only 43
Prior chemotherapy None 18
One line 46
≥ 2 lines 23
unknown 13Wu et al. BMC Cancer 2010, 10:158
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related with OS (HR = 0.213, p = 0.0015; Table 2 and
Figure 3).
Discussion
The survival of patients with metastatic BC varies from
months to several years, and the most common meta-
static site is bone. Metastasis to sites other than bone
often dramatically shortens survival [2,4]. Bone metasta-
sis is often related to ER-positivity and low grade tumor
[16]. Our findings were consistent with previous studies
in that ER positivity and bone-only were associated with a
longer survival [17]. Tumor markers have been proven
previously to have limited or no prognostic value [2,18],
and they were not prognostic markers for survival in this
study . Specifically HER2 status did not contribute as a
prognostic marker perhaps due to the use of trastuzumab
in half of our patients.
When marrow is invaded by BC cells, osteoclasts are
recruited and differentiated at an increased rate by the
production of high amounts of tumor-derived cytokines
Figure 1 Survival curve comparing patients with baseline TRACP 5b activity in the upper third and the lower two thirds using Cox-regres-
sion model.Wu et al. BMC Cancer 2010, 10:158
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such as transforming growth factor β (TGF-β), interleu-
kin-6 (IL-6), parathyroid hormone-related protein
(PTHrP) [19]. It is reasonable to hypothesize that a higher
tumor burden in the marrow could be associated with
Figure 2 The median baseline TRACP 5b activity (U/L) in patients with different overall survival time.
Table 2: Cox-proportional regression analysis results of overall survival time of 100 breast cancer patients with bone 
metastasis.
Patients with available sequential TRACP 5b activities
Total cohort n = 100 Lower 2/3* n = 54 Top 1/3* n = 27
HR** CI** p*** HR CI p HR CI p
Age ns**** - - ns 0.945 0.896 0.997 0.0384 ns - - ns
Baseline TRACP 5b 
activity
3.524 2.066 6.010 < 0.001 - - - - - - - -
ΔmaxTRACP 5b***** - - - - ns - - ns 0.213 0.082 0.555 0.0015
C E A n s- -n s n s- - n sn s - - n s
C A 1 5 . 3 n s- -n s n s- - n sn s - - n s
ER positivity 0.397 0.240 0.656 0.0003 0.260 0.103 0.655 0.0043 0.374 0.148 0.947 0.0379
HER-2/neu positivity ns - - ns ns - - ns ns - - ns
Visceral metastasis 
absent
0.492 0.301 0.802 0.0045 ns - - ns ns - - ns
*. Two Group are classified by the baseline TRACP 5b activity in the top 1/3 (TRACP 5b ≥ 5.736 U/L) and bottom 2/3 (TRACP 5b < 5.736U/L)
**. HR = Hazard ratio; CI = Confidence interval
***. p = p value of each variant
****. ns= Not significant
*****. Maximal interval change of TRACP 5b as a dichotomous variable (Δmax TRACP 5b × 38.59% versus ≤ 38.59%).Wu et al. BMC Cancer 2010, 10:158
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higher cytokine levels, which could further result in
increased numbers of mature osteoclasts and elevated
serum TRACP 5b activity.
We have already shown that serum TRACP 5b activity
correlates with extent of bone metastasis in BC patients
[13]. Since a higher tumor burden is related to a poorer
survival, we tested the hypothesis that elevated serum
TRACP 5b activity, as a measure of extent of bone dis-
e a s e ,  c o u l d  b e  a  m a r k e r  o f  p o o r e r  p r o g n o s i s  i n  B C
patients with bone metastasis. In our study, TRACP 5b
activity was a significant prognostic marker for survival
along with ER status and bone-only metastasis.
Nevertheless, serum TRACP 5b activity may not be ele-
v a t ed  i n  a l l  BC  p a t i e n t s  w i t h  bo n e  m e t a s t a s i s,  o n l y  i n
those with extensive metastasis [14]. Previous receiver
operative characteristic curve analysis showed that,
although serum TRACP 5b activity is highly specific for
bone metastasis, its sensitivity is only 80% [12]. Other
factors to weaken this association could be whether bone
metastasis is osteoblastic, osteolytic or mixed. If the
lesions were primarily osteoblastic, serum TRACP 5b
activity might be lower than those with osteolytic or
mixed lesions (Personal observations by TYC). Baseline
bone metabolic rate of individual patients may also con-
found analysis because age and the presence of osteopo-
rosis have been shown to have impact on serum TRACP
5b activity [12]. For example, serum TRACP 5b activity
may be lower in pre-menopausal patients with bone
metastasis. Although we corrected for age, BC and bone
metastasis afflicts younger woman in Asia than in the
West. Also in this regard, many post-menopausal women
take anti-resorptive drugs to preserve bone health, which
may cause apoptosis of osteoclasts and decrease the
serum TRACP 5b activity [10]. All these confounding fac-
tors may have weakened the power of serum TRACP 5b
activity in reflecting the tumor burden. In fact, some
patients with a lower serum TRACP 5b activity may actu-
ally carry a high tumor burden.
Accordingly, we proposed that only in those patients
with higher serum activity can TRACP 5b genuinely
reflected higher tumor burden. Whereas in those patients
with lower activities, serum TRACP 5b may not be useful
as a prognostic factor. However, the real cutoff value to
differentiate high from low serum TRACP 5b activity is
unknown. Therefore we divided our patients into sub-
groups arbitrarily by the scale of baseline TRACP 5b
activities, i.e. top 1/3 versus remaining 2/3 with the cutoff
value of 5.736 U/L. We indeed found that those patients
with baseline serum TRACP 5b activity higher than 5.736
U/L had a significantly shorter survival than the remain-
ders.
Interval changes of bone markers after treatment in BC
patients with bone metastases have been proposed as
potential prognostic factors. Lipton et al. reported that a
Table 3: Demographic and allocation analysis between highest tertile and lower tertiles
Top 1/3
(n = 33)
(Median ± SD)
Bottom 2/3
(n = 67)
(Median ± SD)
p-value
Age* 49.7 ± 8.48 50.0 ± 9.29 0.995
Survival time (days) * 202 ± 264 700 ± 702 <0.0001
Pre-enrolled time 
(days) *
817 ± 820 1218 ± 1584 0.021
Baseline TRACP 5b* 8.006 ± 3.921 3.063 ± 1.050 <0.0001
CEA* 5.34 ± 83.02 2.50 ± 1102 0.577
CA 15.3* 196.7 ± 648.06 32.59 ± 142.42 <0.0001
Visceral metastasis** Positive 22 35 0.248
Negative 11 32
ER** Positive 16 47 0.156
Negative 12 16
HER** Positive 6 12 1.00
Negative 19 38
Prior chemotherapy ** None 4 14 0.619
One line 16 30
≥ 2 lines 7 16
*: Student t test (2-tailed)
**: Chi-SquareWu et al. BMC Cancer 2010, 10:158
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persistently elevated urinary NTX level was related to
poorer prognosis [6,7]. Early normalization of baseline
elevated NTX was associated with longer event-free and
overall survival times. Additionally, an extremely elevated
baseline urinary NTX was associated with increased
tumor burden in bone and an extremely aggressive dis-
ease. Our results showed that serum TRACP 5b activity
interval change might also be a potential prognostic
marker, but it needs to be validated independently. In
those patients with baseline serum TRACP 5b activities
higher than 5.736 U/L, a ΔmaxTRACP 5b greater than
LSC after treatment had significantly longer OS com-
pared to the rest of the group after adjustment of other
prognostic factors. Serum TRACP 5b activity of more
than 5.736 U/L is probably related to a significant volume
of cancer cells. Furthermore, when interval change of a
biological marker is considered to be of prognostic value
for a specific clinical setting, the LSC of a marker should
be taken into account while interpreting the results. In
our study, the LSC for serum TRACP 5b activity was
Figure 3 Survival curve comparing patients with baseline TRACP 5b activity ≥ 5.736 U/L grouped by ΔmaxTRACP 5b > 38.59% and 
ΔmaxTRACP 5b ≤ 38.59% in a Cox-regression model.Wu et al. BMC Cancer 2010, 10:158
http://www.biomedcentral.com/1471-2407/10/158
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38.59% determined from 15 early BC patients. When we
dichotomized those patients whose serum TRACP 5b
activities were higher than 5.736 U/L into 2 groups based
on response, we were able to demonstrate that patients
with a ΔmaxTRACP 5b > 38.59% had a significantly longer
survival than those without. However, this correlation
was not existent when all patients were considered
together. Other confounding factors such as ER status
and bone-only metastasis correlated more strongly with
the OS. ΔmaxTRACP 5b lost its statistical significance as a
prognostic marker for survival in the lower tertile groups.
Our explanation is that serum TRACP 5b may not reflect
the real tumor burden in those patients with lower activi-
ties. This may have biased the result when all patients
were included. Another possible explanation might be
that ΔmaxT R A C P  5 b  o n l y  c o r r e l a t e d  w i t h  t r e a t m e n t
response, which was not a strong prognostic marker for
OS.
There are several limitations of this study. Firstly this is
a retrospective study and patients did not receive uniform
treatment. Nevertheless, it does reflect the real context of
clinical practice, and effects due to specific treatments
were not our primary objective. Secondly, the patient
numbers are relatively small and the results could not be
interpreted by stratification. Thirdly, tissues were not
adequate enough or not available for determining ER sta-
tus in 9 patients and HER2 in 25 patients. Fourthly, the
cut-off value of 5.736 U/L was arbitrarily determined by
dividing patients into top 1/3 and bottom 2/3 according
to the scale of serum TRACP 5b activity. This cut-off may
not be the same in different laboratories and with differ-
ent assays. Fifthly, 19 of the 100 patients in this study did
not have serial TRACP 5b data to calculate the associa-
tion between its interval change and the overall survival
time. This may have biased the final results.
Conclusion
Our study, deemed as a concept proving study, has shed
light on the relative diagnostic and prognostic value of
serum TRACP 5b in BC patients with bone metastasis.
The research effort is exploratory and hypothesis-gener-
ating only, given the small sample size and certain study
design limitations. To determine the true value of
TRACP 5b as a prognostic marker for all patients with
bone metastasis will require a prospective phase II study
over a longer period including more patients to allow for
more refined stratification.
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